Related Experiment Video
Updated: Sep 9, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
THE IMPACT OF DISEASE-MODIFYING MEDICATIONS ON THE LIPID PROFILE OF PATIENTS WITH ISCHEMIC HEART DISEASE
N Mohammad1, O Darweesh2, M Merkhan3
11Department of Pharmacy, Al-Qalam University College, Kirkuk, Iraq.
Insights
Combination therapy with disease-modifying medications significantly reduces lipid parameters in patients with ischemic heart disease (IHD). This approach offers a valuable strategy for managing IHD risk factors like myocardial infarction (MI) and stroke.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ischemic heart diseases (IHD) involve coronary artery narrowing, increasing risks of myocardial infarction (MI) and stroke.
- High morbidity and mortality associated with IHD pose significant healthcare challenges.
Purpose of the Study:
- To evaluate the role of disease-modifying medications (DMMs) in managing IHD risk factors.
- Specific DMMs investigated include statins, SGLT2 inhibitors, and PCSK9 inhibitors.
Main Methods:
- A randomized controlled trial involving 500 patients across four treatment groups: statins, SGLT2 inhibitors, PCSK9 inhibitors, and combination therapy.
- Serum lipid parameters were assessed at baseline and 12 months post-treatment.
Main Results:
- All treatment groups showed a reduction in lipid parameters after 12 months.
- Combination therapy yielded the most significant lipid reduction (-74±10 mg/dL, p<0.05).
- Age and gender showed minor modulation of treatment response.
Conclusions:
- Combination DMM therapy is a promising strategy for managing lipid parameters in IHD patients.
- This approach may reduce risks of stroke and MI, offering an additional therapeutic role in cardiovascular disease management.
Background:
Ischemic heart diseases (IHD) refer to narrowing of coronary artery resulting in partial or complete stenosis making patients susceptible to myocardial infarction (MI) and stroke challenging the healthcare provider due to high risk of morbidity and mortality. The aim of this study was directed to identify the role various disease-modifying medications (DMMs) in the treatment of IHD-associated risk factors, including statins, sodium-glucose transporter (SGLT2) inhibitors, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Methods:
A total of 500 patients recruited from multicentre were enrolled in this randomized controlled clinical trial. The patients were subdivided into 4-treatment groups, including statin group, SGLT-2 inhibitors group, PCSK9 inhibitors group, or combination therapy group. The serum lipid parameters were measured initially and after 12 months post-therapy.
Results:
The treatment groups have demonstrated reduction of lipid parameters at the end of the 12-months of study period. The combination therapy has provided the greatest reduction (-74±10 mg/dL, p<0.05). Age and gender has slightly modulated the response to these medications.
Conclusion:
The combination of DMMs carry may be a valuable tool for managing the lipid parameters reducing risk factors that prone IHD-patients to stroke and MI, suggesting additional therapeutic role for cardiovascular disease managements.
Related Concept Videos
01:26Atherosclerosis III: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:21Rheumatic Heart Disease III: Medical Management
01:27Peripheral Artery Disease III: Interprofessional Care